Treatment of Androgenetic Alopecia in Males With Theradome™ LH80 PRO

Inclusion Criteria: * Subject must be diagnosed with androgenetic alopecia with Norwood Hamilton hair loss scale of IIa, III vertex, IV and V. * Subject must have Fitzpatrick skin type scale I to IV. * Subject must be able to visit clinic site for baseline, 13 week and 26 week study visits and attend 2 visits by phone ( 6 and 19). * Hair must be at least 1 inch in length. The hairstyle and length shall be the same for each site visit. Subjects are instructed to have their hair cut/styled 1-5 days in advance of a site visit. * Be willing to undergo all study procedures including consent for global photographs of hair loss/growth and a 1 mm tattoo to mark the macrophotography site along the indicated transition area of the scalp between the hairline and the balding area of the vertex. * Be willing to avoid use of wigs, hairpieces, and/or hair extensions during the study period. * Ability to communicate effectively with study personnel. * Agrees to abstain from use of any hair growth affecting oral or topical medication including over the counter and herbal medications, minoxidil, finasteride or dutasteride during the course of this study Exclusion Criteria: * History of taking Propecia or any other hair growth supplements for 12 months prior to enrollment. * History of using Rogaine for 6 months prior to enrollment. * Subject must have no previous hair transplant, cell treatment, micro needling, or any other treatment in the last 6 months in the scalp. * Subject is currently suffering from an active autoimmune disease such as serum lupus erythematosus, or alopecia areata. * Currently suffering from dermatologic condition in the treatment area or has a significant scar in the hair treatment area that, in the opinion of the investigator, will make hair growth difficult (such as systemic burns, etc). * Subject has a sensitivity or allergy to tattoo ink. * Clinically significant medical or psychiatric illness currently or within 30 days of study screening as determined by the investigator. * Employed by sponsor, clinic site, or entity associated with the conduct of the study.